Showing 1401-1410 of 2403 results for "".
- Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billionhttps://practicaldermatology.com/news/20140528-valeant_pharmaceuticals_to_sell_filler_and_toxin_assets_to_nestle_for_14_billion/2459228/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquis
- Pliaglis Launches in Europehttps://practicaldermatology.com/news/20130502-pliaglis_launches_in_europe/2459551/Nuvo Research Inc. and Galderma Pharma, S.A. launched Pliaglis (lidocaine and tetracaine) Cream 7%/7% in Europe. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, and licenses have been issued in 14 of the 16 European cou
- Galderma Acquires Spirighttps://practicaldermatology.com/news/20121213-galderma_acquires_spirig/2459659/Galderma Pharma S.A. and Spirig Pharma A.G. entered into a definitive agreement under which Galderma will acquire Spirig. Spirig's products treat conditions such as solar damage, skin barrier function impairment, and actinic keratosis. Leading br
- Valeant, Galderma Revise Agreement Termshttps://practicaldermatology.com/news/20121210-valeant_galderma_revise_agreement_terms/2459661/Valeant Pharmaceuticals International, Inc. reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and co
Physician Spotlight: Jeffrey S. Dover, MD, FRCPC
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-jeffrey-s-dover-md-frcpc/23854/Physician Spotlight: Jeffrey M. Cohen, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-jeffrey-m-cohen-md/23555/The Colemans: Dermatology as a Father-Son(s) Tradition
https://practicaldermatology.com/topics/feature/colemans-dermatology-father-sons-tradition/26956/The Colemans: Dermatology as a Father-Son(s) TraditionJournal Club: S. Aureus-Driven AD Exacerbation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-s-aureus-driven-ad-exacerbation/32404/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses a recent Journal of Drugs in Dermatology article about the need for a novel treatment for S. aureus exacerbated atopic dermatitis with Adelaide Hebert, MD.Schachner LA, Andriessen A, Gonzalez ME, Lal K, Hebert AA, E“S or “C” Corporation for Your Practice
https://practicaldermatology.com/topics/practice-management/s-or-c-corporation-for-your-practice/21503/Maximize tax deductions by using both.Physician Spotlight: Jeffrey P. Callen, MD, FACP, FAAD, MACR
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-jeffrey-p-callen-md-facp-faad-macr/20625/Understanding cutaneous manifestations of systemic disease